Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate

China Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate, Find details about China Pemetrexed, Anti-Cancer Intermediate from Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate

Model NO.
PX-A
CAS
52-24-4
Sample
Free
Usage
API
Product Nane
Pemetrexed
Colour
White
Appearance
White Powder
Supply
Bulk
Trademark
OEM
Transport Package
25kg/Drum
Specification
25KG/Bag
Origin
China
HS Code
3001200010
Model NO.
PX-A
CAS
52-24-4
Sample
Free
Usage
API
Product Nane
Pemetrexed
Colour
White
Appearance
White Powder
Supply
Bulk
Trademark
OEM
Transport Package
25kg/Drum
Specification
25KG/Bag
Origin
China
HS Code
3001200010
Product Description

Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate

Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate

Product Name
Pemetrexed disodium hemipenta hydrate
Appearance
White or off- white powder
Assay
99%min, 98.0% --101.0%
Test
HPLC 
Certificate
ISO 9001 
CAS
357166-30-4
MF2(C20H19N5Na2O6).5(H2O)
Storage Temperature
Cool Dry Place

Despcription

Pemetrexed disodium heptahydrate is an organic sodium salt that is the heptahydrate form of pemetrexed disodium. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). It has a role as an antimetabolite, an antineoplastic agent, an EC 1.5.1.3 (dihydrofolate reductase) inhibitor, an EC 2.1.1.45 (thymidylate synthase) inhibitor and an EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor. It is an organic sodium salt and a hydrate. It contains a pemetrexed disodium.

Function

Malignant pleural mesotheliomaPemetrexed Krka in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Krka in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Krka is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Krka is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.
Detailed Photos
Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate
Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate

 

Our Advantages

Anti-Cancer Intermediate CAS 123910-88-3 Methyl 4- (4-hydroxybutyl) Benzoate for Pemetrexed Disodium API Intermediate